← Evidence map

ArticleCureus2026

Impact of the 21-Gene Oncotype DX Recurrence Score on Adjuvant Chemotherapy Decision-Making in Invasive Ductal Carcinoma: A Real-World Analysis From a Single Japanese Institution.

Hirofumi Terakawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Impact of the 21-Gene Oncotype DX Recurrence Score on Adjuvant Chemotherapy Decision-Making in Invasive Ductal Carcinoma: A Real-World Analysis From a Single Japanese Institution. | OpenQuestion